UnknownPhase 4

Topical Tacrolimus in Vernal Keratoconjunctivitis

Saudi Arabia20 participantsStarted 2013-04

Plain-language summary

The main aim of this study is to evaluate the efficacy and safety of topical tacrolimus 0.01% eyedrops in patients with vernal keratoconjunctivitis.

Who can participate

Age range6 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * with bilateral symmetrical palpebral and limbal vernal keratoconjunctivitis * Patients 6-18 years of age Exclusion Criteria: * Pregnant patients * Patients on systemic therapy for other allergic disorders * Patients who cannot come for follow-up * Patients who are on other topical medications for other comorbid ocular conditions

What they're measuring

The efficacy of Topical Tacrolimus in Vernal Keratoconjunctivitis

Timeframe: Five months

Trial details

NCT IDNCT02456025

SponsorThe Eye Center and The Eye Foundation for Research in Ophthalmology

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-12

Contact for this trial

Samir S Shoughy

0096614649614 samir.shawki@hotmail.com

View on ClinicalTrials.gov More Vernal Keratoconjunctivitis trials